The protective effect of thalidomide on left ventricular function in a rat model of diabetic cardiomyopathy

European Journal of Heart Failure

Volumn 12, Issue 10, 2010, Pages 1051-1060

  Kim, Dae Hee ^a   Kim, Yong Jin ^a   Chang, Sung A ^a   Lee, Hye Won ^a   Kim, Ha Na ^a   Kim, Hyung Kwan ^a   Chang, Hyuk Jae ^a   Sohn, Dae Won ^a   Park, Young Bae ^a  

^a Seoul National University Hospital   (South Korea)

Author keywords

Diabetic cardiomyopathy; Streptozocin; Thalidomide; Ventricular function

Indexed keywords

COLLAGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD LEVEL; CLINICAL EXAMINATION; COMPLIANCE [(]PHYSICAL[)]; CONTROL GROUP; CONTROLLED STUDY; DETERIORATION; DIABETIC CARDIOMYOPATHY; DIABETOGENESIS; DIASTOLE; DIASTOLIC BLOOD PRESSURE; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE; HEART MUSCLE FIBROSIS; HEART PRELOAD; HEART PROTECTION; HEMODYNAMICS; HISTOPATHOLOGY; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; LUNG; MALE; MITRAL ANNULOPLASTY; NONHUMAN; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; STREPTOZOCIN DIABETES; STROKE; SYSTOLE; SYSTOLIC BLOOD PRESSURE; TISSUE LEVEL;

ANALYSIS OF VARIANCE; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; COLLAGEN; DIABETES MELLITUS, TYPE 1; DIABETIC CARDIOMYOPATHIES; FIBROSIS; HEART VENTRICLES; HEMODYNAMICS; HYPERTROPHY, LEFT VENTRICULAR; IMMUNOSUPPRESSIVE AGENTS; MALE; MATRIX METALLOPROTEINASE 9; RATS; RATS, SPRAGUE-DAWLEY; STATISTICS, NONPARAMETRIC; STREPTOZOCIN; SYSTOLE; THALIDOMIDE; VENTRICULAR FUNCTION, LEFT;

EID: 77957239226     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfq103     Document Type: Article

References (35)

1. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007;115: 3213-3223.
2. Poirier P, Bogaty P, Garneau C, Marois L, Dumesnil JG. Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care 2001;24:5-10.
3. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979;241:2035-2038.
4. Tschope C, Walther T, Escher F, Spillmann F, Du J, Altmann C, Schimke I, Bader M, Sanchez-Ferrer CF, Schultheiss HP, Noutsias M. Transgenic activation of the kallikrein-kinin system inhibits intramyocardial inflammation, endothelial dysfunction and oxidative stress in experimental diabetic cardiomyopathy. FASEB J 2005;19:2057-2059.
5. Sjoholm A, Nystrom T. Inflammation and the etiology of type 2 diabetes. Diabetes Metab Res Rev 2006;22:4-10.
6. Nian M, Lee P, Khaper N, Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 2004;94:1543-1553.
7. Meldrum DR. Tumor necrosis factor in the heart. Am J Physiol 1998;274: R577-R595.
8. Westermann D, Rutschow S, Van Linthout S, Linderer A, Bucker-Gartner C, Sobirey M, Riad A, Pauschinger M, Schultheiss HP, Tschope C. Inhibition of p38 mitogen-activated protein kinase attenuates left ventricular dysfunction by mediating pro-inflammatory cardiac cytokine levels in a mouse model of diabetes mel-litus. Diabetologia 2006;49:2507-2513.
9. Raje N, Anderson K. Thalidomide-a revival story. N Engl J Med 1999;341: 1606-1609.
10. Tschope C, Walther T, Yu M, Reinecke A, Koch M, Seligmann C, Heringer SB, Pesquero JB, Bader M, Schultheiss H, Unger T. Myocardial expression of rat bra-dykinin receptors and two tissue kallikrein genes in experimental diabetes. Immu-nopharmacology 1999;44:35-42.
11. Georgakopoulos D, Mitzner WA, Chen CH, Byrne BJ, Millar HD, Hare JM, Kass DA. In vivo murine left ventricular pressure-volume relations by miniaturized conductance micromanometry. Am J Physiol 1998;274:H1416-H1422.
12. Pacher P, Nagayama T, Mukhopadhyay P, Batkai S, Kass DA. Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nature Protoc 2008;3:1422-1434.
13. Weiss JL, Frederiksen JW, Weisfeldt ML. Hemodynamic determinants of the time-course of fall in canine left ventricular pressure. J Clin Invest 1976;58:751-760.
14. Malkusch W, Rehn B, Bruch J. Advantages of Sirius Red staining for quantitative morphometric collagen measurements in lungs. Exp Lung Res 1995;21:67-77.
15. Tschope C, Spillmann F, Rehfeld U, Koch M, Westermann D, Altmann C, Dendorfer A, Walther T, Bader M, Paul M, Schultheiss HP, Vetter R. Improvement of defective sarcoplasmic reticulum Ca2+ transport in diabetic heart of transgenic rats expressing the human kallikrein-1 gene. FASEB J 2004;18: 1967-1969.
16. Westermann D, Van Linthout S, Dhayat S, Dhayat N, Escher F, Bucker-Gartner C, Spillmann F, Noutsias M, Riad A, Schultheiss HP, Tschope C. Cardioprotective and anti-inflammatory effects of interleukin converting enzyme inhibition in experimental diabetic cardiomyopathy. Diabetes 2007;56:1834-1841.
17. Westermann D, Rutschow S, Jager S, Linderer A, Anker S, Riad A, Unger T, Schultheiss HP, Pauschinger M, Tschope C. Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyo-pathy: the role of angiotensin type 1 receptor antagonism. Diabetes 2007;56: 641-646.
18. Tsutamoto T, Wada A, Ohnishi M, Tsutsui T, Ishii C, Ohno K, Fujii M, Matsumoto T, Yamamoto T, Takayama T, Dohke T, Horie M. Transcardiac increase in tumor necrosis factor-alpha and left ventricular end-diastolic volume in patients with dilated cardiomyopathy. Eur J Heart Fail 2004;6:173-180.
19. Vaz Perez A, Doehner W, von Haehling S, Schmidt H, Zimmermann AV, Volk HD, Anker SD, Rauchhaus M. The relationship between tumor necrosis factor-alpha, brain natriuretic peptide and atrial natriuretic peptide in patients with chronic heart failure. Int J Cardiol 2009;
20. Dunlay SM, Weston SA, Redfield MM, Killian JM, Roger VL. Tumor necrosis factor-alpha and mortality in heart failure: a community study. Circulation 2008; 118:625-631.
21. Yokoyama T, Nakano M, Bednarczyk JL, McIntyre BW, Entman M, Mann DL. Tumor necrosis factor-alpha provokes a hypertrophic growth response in adult cardiac myocytes. Circulation 1997;95:1247-1252.
22. Sun M, Chen M, Dawood F, Zurawska U, Li JY, Parker T, Kassiri Z, Kirshenbaum LA, Arnold M, Khokha R, Liu PP. Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state. Circulation 2007;115:1398-1407.
23. Rodrigues B, Cam MC, McNeill JH. Metabolic disturbances in diabetic cardiomyo-pathy. Mol Cell Biochem 1998;180:53-57.
24. Leichman JG, Aguilar D, King TM, Vlada A, Reyes M, Taegtmeyer H. Association of plasma free fatty acids and left ventricular diastolic function in patients with clinically severe obesity. Am J Clin Nutr 2006;84:336-341.
25. Nguyen MT, Satoh H, Favelyukis S, Babendure JL, Imamura T, Sbodio JI, Zalevsky J, Dahiyat BI, Chi NW, Olefsky JM. JNK and tumor necrosis factor-alpha mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes. J Biol Chem 2005; 280:35361-35371.
26. Hasselbaink DM, Glatz JF, Luiken JJ, Roemen TH, Van der Vusse GJ. Ketone bodies disturb fatty acid handling in isolated cardiomyocytes derived from control and diabetic rats. Biochem J 2003;371:753-760.
27. Lv P, Paul SC, Xiao Y, Liu S, Luo H. Effects of thalidomide on the expression of adhesion molecules in rat liver cirrhosis. Mediators Inflamm 2006;2006:93253.
28. Yndestad A, Vinge LE, Bjornerheim R, Ueland T, Wang JE, Froland SS, Attramadal H, Aukrust P, Oie E. Thalidomide attenuates the development of fibrosis during post-infarction myocardial remodelling in rats. Eur J Heart Fail 2006;8:790-796.
29. Jacobson JM. Thalidomide: a remarkable comeback. Expert Opin Pharmacother 2000;1:849-863.
30. Adlard JW. Thalidomide in the treatment of cancer. Anticancer Drugs 2000;11: 787-791.
31. Arroba AI, Lechuga-Sancho AM, Frago LM, Argente J, Chowen JA. Increased apoptosis of lactotrophs in streptozotocin-induced diabetic rats is followed by increased proliferation. J Endocrinol 2006;191:55-63.
32. Gullestad L, Ueland T, Fjeld JG, Holt E, Gundersen T, Breivik K, Folling M, Hodt A, Skardal R, Kjekshus J, Andreassen A, Kjekshus E, Wergeland R, Yndestad A, Froland SS, Semb AG, Aukrust P. Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double-blind, placebo-controlled study. Circulation 2005;112:3408-3414.
33. Loh HK, Sahoo KC, Kishore K, Ray R, Nag TC, Kumari S, Arya DS. Effects of tha-lidomide on isoprenaline-induced acute myocardial injury: a haemodynamic, his-topathological and ultrastructural study. Basic Clin Pharmacol Toxicol 2007;100: 233-239.
34. Chong LW, Hsu YC, Chiu YT, Yang KC, Huang YT. Anti-fibrotic effects of thali-domide on hepatic stellate cells and dimethylnitrosamine-intoxicated rats. J Biomed Sci 2006;13:403-418.
35. Yoon YS, Uchida S, Masuo O, Cejna M, Park JS, Gwon HC, Kirchmair R, Bahlman F, Walter D, Curry C, Hanley A, Isner JM, Losordo DW. Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: restoration of microvascular homeo-stasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor. Circulation 2005;111:2073-2085.